Novartis AG
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NVSEF | 0QOK.IL | AMGN | AZN | 0QYQ.IL | BIIB | |
|---|---|---|---|---|---|---|
| Market cap | 299.67B | 334.46B | 258.68B | 293.14B | 215.56B | 37.61B |
| P/E (TTM) | 30.3 | 30.3 | 27.7 | 26.7 | 39.8 | 110.2 |
| Forward P/E | — | — | 19.5 | 16.7 | — | 15.6 |
| Price/book | 8.0 | 11.9 | 18.0 | 5.7 | 10.2 | 2.0 |
| Dividend yield | 2.98% | 3.99% | 2.11% | 1.69% | 3.81% | — |
| 1-year change | +32.23% | +22.46% | +51.61% | +12.81% | +38.91% | +62.35% |
| Today | +0.77% | +21.69% | +3.73% | +2.79% | +0.58% | +2.22% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All NVSEF news ›Novartis AG Stock (NVS) Moved Up by 3.34% on Nov 4: A Full Analysis
TradingKey Novartis AG Stock (NVS) Moved Up by 3.34% on Nov 4: A Full Analysis Novartis AG (NVS) moved up by 3.34%. The Pharmaceuticals & Medical Research sector is up by 2.48%. The company outperformed the industry. Top 3 stocks b
Major Setback for Novartis as Experimental Cholesterol Drug Fails
Los Angeles: The recent failure of a Novartis experimental heart drug in a large trial raised questions among cardiologists and investors about the widely held idea that reducing levels of a genetically set cholesterol carrier called…
Korea approves Novartis' Vanrafia, first selective ETA blocker for IgA nephropathy
Novartis Korea said Wednesday that Korea has approved Vanrafia (atrasentan) for adults with IgA nephropathy, making it the country's first selective endothelin A (ETA) receptor antagonist approved to treat the kidney disease. The Ministry…
Novartis Records USD 2.2 Billion in Charges After Drug Trial Setbacks, Raises 2026 Profit Outlook
Zurich: Novartis recorded about USD 2.2 billion in charges related to two drugs that failed in late-stage studies last month, even as it boosted its full-year profit expectations on Tuesday. The Swiss drugmaker's operating income fell 61%…
Novartis MS Drug Cuts Relapses by Up to 35%, Falls Short of Analyst Expectations
London: Swiss drugmaker Novartis' oral multiple sclerosis (MS) drug remibrutinib meaningfully reduced relapses in patients, according to data presented at a medical conference in Toronto on Friday, but less than analysts had expected. The…
South Korea Approves Novartis Banrapia for Kidney Disease IgAN: First Country Outside US
Vanrafia (atrasentan) wins MFDS approval in South Korea for IgA nephropathy, making Korea the first country outside the US to clear a selective ET-A receptor antagonist for kidney disease.
How Novartis optimized its supply chain with real-time risk insight
How Xoople transforms Earth data into business insights How AI drove Daikin’s business transformation from complexity to agility How humanoid robotics are strengthening complex industrial work Can disciplined ambition unlock growth in a…
Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target
pharma.economictimes.indiatimes.com
Novartis Exits BrainTransporter Deal with BioArctic 14 Months After Signing
Novartis exits its BrainTransporter deal with BioArctic 14 months after signing, citing an internal portfolio decision unrelated to the platform. Novartis has terminated its collaboration with BioArctic AB, ending a partnership designed to…
Novartis ends BioArctic brain-delivery deal worth up to $802M
Swedish biotech BioArctic has lost a partnership with Swiss drugmaker Novartis to develop a potential treatment for neurodegenerative diseases using its BrainTransporter technology. The termination eliminates the prospect of up to $772…
More from 1 other outlet
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com36
- seekingalpha.com7
- novartis.com6
- tradingview.com5
- openpr.com4
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 99 articles, not a forecast.